Fulvestrant in Metastatic Breast Cancer

• Status: Unknown status
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a prospective study of the role of fulvestrant in combination with ovarian function suppression as first-line therapy in premenopausal patients with metastatic hormone receptor-positive breast cancer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Estradiol; Fulvestrant; Goserelin

Criteria

Inclusion Criteria:

• Women with age 30-50 years old (premenopause).

• Histological confirmation of metastatic disease.

• Hormonal receptor positive.

• Endocrine therapy for early disease had been completed more than 12 months before the study (patients who was not resistance to hormonal therapy).

• Metastatic breast cancer at presentation.

• Patients had not received any previous systemic therapy for metastatic disease.

• Performance status (ECOG) 0-2.

Exclusion Criteria:

• Patient >55 years old.

• Non-histologically diagnosed.

• Hormonal receptor negative

• Non metastatic

• received previous line therapy in the metastatic setting.

• Patient with performance >2.

• Patient with co-morbidity

• Patients with brain metastasis